Our Science

Eidolon is Fine-tuning Inflammation with Engineered Microbial Protein Combinations

Current Immunotherapies Don’t Fine-tune Inflammation

60%+

of advanced tumours do not respond to immunotherapy

20%

of immunotherapy patients face immune-related adverse effects

  • Cytokines can activate the NF-κB, MAPK and JAK-STAT signalling pathways to trigger acute and chronic inflammation.

  • Acute inflammation such as damage-associated molecular patterns (DAMPs) from immunogenic cell death can stimulate dendritic cell and T cell activation.

  • Chronic and dysregulated inflammation via CXCL1/2, IL-6 and IL-8 can promote immunosuppression, angiogenesis, and therapy resistance.

Fine-tuning Inflammation to Balance Immune Response

Our Modular Microbial Protein Combinations are:

  • Each protein precisely target specific inflammatory pathways.

  • Proteins synergise with each other to amplify beneficial inflammatory signature and dampen harmful ones.

  • Individual proteins can be swapped with one another to modulate cytokines with cancer type/stage-specific roles.